Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer

By Nielsen Kirsten  

Breast Cancer Research and Treatment, Vol. 127, Iss. 2, 2011-06 ,pp. : 345-355

Springer Publishing Company

Access to resources Recommend Favorite

Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer

By Rutqvist Lars   Johansson Hemming   Group on behalf of the Stockholm Breast Cancer Study  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 133-145

Informa Healthcare

Access to resources Recommend Favorite

MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen

By Tengström Maria   Mannermaa Arto   Kosma Veli-Matti   Soini Ylermi   Hirvonen Ari   Kataja Vesa  

Acta Oncologica, Vol. 53, Iss. 6, 2014-06 ,pp. : 769-775

Informa Healthcare

Access to resources Recommend Favorite

HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen

By              

International Journal of Oncology, Vol. 47, Iss. 4, 2015-01 ,pp. : 1311-1320

Spandidos Publications

Access to resources Recommend Favorite

c-erbB-2 Expression and Benefit From Adjuvant Chemotherapy and Radiotherapy of Breast Cancer

By Stal O.   Sullivan S.   Wingren S.   Skoog L.   Rutqvist L.E.   Carstensen J.M.   Nordenskjold B.  

European Journal of Cancer, Vol. 31, Iss. 13, 1995-12 ,pp. : 2185-2190

Elsevier

Access to resources Recommend Favorite